Tetsuya Fujimori

Director/Board Member at Cenegenics Japan KK

55 year

Health Technology

Consumer Services

Profile

Tetsuya Fujimori is currently the Representative Director at Cenegenics Japan KK since 2020.
Prior to this, he worked as an Independent Outside Director at tella, Inc. Mr. Fujimori completed his undergraduate degree from Osaka City University in 1995.

Tetsuya Fujimori active positions

Companies	Position	Start
Cenegenics Japan KK Cenegenics Japan KK Medical SpecialtiesHealth Technology Cenegenics Japan KK engages in the advanced medical support business using genes, cells, and tissues. The company was founded on March 23, 2020 and is headquartered in Tokyo, Japan.	Director/Board Member	2020-02-29

All active positions of Tetsuya Fujimori

Former positions of Tetsuya Fujimori

Companies	Position	End
TELLA, INC.	Director/Board Member	-

See the detail of Tetsuya Fujimori's experience

Training of Tetsuya Fujimori

Osaka City University

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Tetsuya Fujimori's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Cenegenics Japan KK Cenegenics Japan KK Medical SpecialtiesHealth Technology Cenegenics Japan KK engages in the advanced medical support business using genes, cells, and tissues. The company was founded on March 23, 2020 and is headquartered in Tokyo, Japan.	Health Technology
tella, Inc. tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan.	Health Technology